A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat-Reference-Cited by-同舟云学术

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat

Published:2020-06-19 Issue:7 Volume:9 Page:374-383
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Abrams Ruth¹,Kaddi Chanchala D.¹,Tao Mengdi¹,Leiser Randolph J.¹,Simoni Giulia²,Reali Federico²^ORCID,Tolsma John³,Jasper Paul³,Rijn Zachary¹,Li Jing¹,Niesner Bradley¹,Barrett Jeffrey S.¹,Marchetti Luca²,Peterschmitt M. Judith⁴,Azer Karim¹,Neves‐Zaph Susana¹^ORCID

Affiliation:

1. Translational Disease Modelling Digital Data Science Sanofi Bridgewater New Jersey USA

2. Fondazione The Microsoft Research ‐ University of Trento Centre for Computational and Systems Biology (COSBI) Rovereto Italy

3. RES Group Inc Needham Massachusetts USA

4. Sanofi Genzyme Cambridge Massachusetts USA

Funder

Sanofi

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link